SG136804A1 - Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications - Google Patents

Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications

Info

Publication number
SG136804A1
SG136804A1 SG200500152-4A SG2005001524A SG136804A1 SG 136804 A1 SG136804 A1 SG 136804A1 SG 2005001524 A SG2005001524 A SG 2005001524A SG 136804 A1 SG136804 A1 SG 136804A1
Authority
SG
Singapore
Prior art keywords
cell
antibody
treatment
combination
related applications
Prior art date
Application number
SG200500152-4A
Inventor
Nabil Hanna
Kandasamy Hariharan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/772,938 external-priority patent/US20020006404A1/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of SG136804A1 publication Critical patent/SG136804A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Use of an anti-B7 antibody and at least one B cell depleting antibody for manufacture of a medicament for treating a B cell malignancy.
SG200500152-4A 2000-07-12 2001-05-16 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications SG136804A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21770600P 2000-07-12 2000-07-12
US09/772,938 US20020006404A1 (en) 1999-11-08 2001-01-31 Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications

Publications (1)

Publication Number Publication Date
SG136804A1 true SG136804A1 (en) 2007-11-29

Family

ID=26912176

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200500152-4A SG136804A1 (en) 2000-07-12 2001-05-16 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications

Country Status (11)

Country Link
EP (1) EP1305045A1 (en)
JP (1) JP2004502742A (en)
KR (2) KR20030031957A (en)
CN (1) CN1446104A (en)
AU (2) AU2001264612C1 (en)
CA (1) CA2415100A1 (en)
IL (1) IL153764A0 (en)
MX (1) MXPA03000306A (en)
NO (1) NO20030128L (en)
SG (1) SG136804A1 (en)
WO (1) WO2002004021A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642596A3 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
EP1299128A2 (en) * 2000-06-20 2003-04-09 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
KR20040023565A (en) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CN1308448C (en) 2000-10-20 2007-04-04 中外制药株式会社 Degraded TPO agonist antibody
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002243718B2 (en) * 2001-01-31 2007-12-06 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
WO2002078766A2 (en) * 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
AU2003210266A1 (en) * 2002-02-14 2003-09-04 Bioinvent International Ab Treatment, diagnosis and imaging of disease
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
KR20100050587A (en) 2002-10-17 2010-05-13 젠맵 에이/에스 Human monoclonal antibodies against cd20
JP4351674B2 (en) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド Immunoglobulin variants and their use and use
JP2004279086A (en) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc Radiation image conversion panel and method for manufacturing it
JPWO2004087763A1 (en) * 2003-03-31 2006-07-27 中外製薬株式会社 Modified antibody against CD22 and use thereof
RS51686B (en) 2003-04-09 2011-10-31 Genentech Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
PT1631313E (en) 2003-06-05 2015-07-02 Genentech Inc Combination therapy for b cell disorders
BRPI0415457A (en) 2003-10-16 2006-12-05 Micromet Ag cytotoxically active cd3 specific binding construct, its production process, composition comprising the same, nucleic acid sequence, vector, host, its uses in the preparation of a pharmaceutical composition and kit comprising the same
EP2236172A1 (en) * 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
TW201422238A (en) 2004-06-04 2014-06-16 Genentech Inc Use of CD20 antibody in treatment of multiple sclerosis and an article for the use
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
AU2006214121B9 (en) * 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
KR101374454B1 (en) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 Methods for producing polypeptides by regulating polypeptide association
TW200722518A (en) 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
JP5129122B2 (en) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー Combination of antibodies and glucocorticoids for cancer treatment
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
JP5068167B2 (en) 2005-06-10 2012-11-07 中外製薬株式会社 Stabilizer for protein preparation containing meglumine and use thereof
CN105012953B (en) 2005-07-25 2018-06-22 阿普泰沃研发有限责任公司 B- cells are reduced with CD37- specificity and CD20- specific binding molecules
JP2009502936A (en) 2005-07-25 2009-01-29 トルビオン ファーマシューティカルズ， インコーポレイテッド Single dose of CD20 specific binding molecule
WO2007019865A2 (en) 2005-08-18 2007-02-22 Genmab A/S Therapy with cd4 binding peptides and radiation
ES2400660T3 (en) 2005-11-01 2013-04-11 Novartis Ag Uses of anti-CD40 antibodies
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
BRPI0710826A2 (en) 2006-04-21 2011-08-23 Novartis Ag antagonist anti-cd40 antibody pharmaceutical compositions
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
AU2008275229B2 (en) 2007-07-09 2014-11-06 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2008312406B2 (en) 2007-10-16 2014-03-06 Ares Trading S.A. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201438738A (en) 2008-09-16 2014-10-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
RU2639288C2 (en) 2009-08-11 2017-12-20 Дженентек, Инк. Proteins production in cultural media without glutamine
RU2573994C2 (en) 2010-02-10 2016-01-27 Иммьюноджен, Инк Anti-cd20 antibodies and thereof application
ES2748347T3 (en) 2010-03-12 2020-03-16 Debiopharm Int Sa CD37 binding molecules and immunoconjugates thereof
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
JP6534615B2 (en) 2013-09-27 2019-06-26 中外製薬株式会社 Method for producing polypeptide heteromultimer
MA41459A (en) 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
AU2016276158B2 (en) 2015-06-08 2022-06-30 Debiopharm International, S.A. Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
LT3313879T (en) 2015-06-24 2022-03-25 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
BR112018003147A2 (en) 2015-08-28 2018-09-18 Debiopharm International S.A. cd37 antibodies and testing
EA201890613A1 (en) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс POLYPEPTIDES CONNECTING CD3
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CA3003399A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
GB2578037A (en) 2017-05-24 2020-04-15 Als Therapy Development Inst Therapeutic anti-CD40 ligand antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5843439A (en) * 1992-11-13 1998-12-01 Anderson; Darrell R. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6287537B1 (en) * 1993-09-16 2001-09-11 The Regents Of The University Of Michigan Radioimmunotherapy of lymphoma using anti-CD20 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5843439A (en) * 1992-11-13 1998-12-01 Anderson; Darrell R. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6287537B1 (en) * 1993-09-16 2001-09-11 The Regents Of The University Of Michigan Radioimmunotherapy of lymphoma using anti-CD20 antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CD40/CD40 LIGAND INTERACTIONS IN NORMAL, REACTIVE AND MALIGNANT LYMPHO-HEMATOPOIETIC TISSUES *
INCREASED INHIBITION OF PROLIFERATION OF HUMAN B CELL LYMHOMAS FOLLO *

Also Published As

Publication number Publication date
KR20080039547A (en) 2008-05-07
MXPA03000306A (en) 2004-04-05
EP1305045A1 (en) 2003-05-02
WO2002004021A9 (en) 2003-01-16
AU6461201A (en) 2002-01-21
CN1446104A (en) 2003-10-01
CA2415100A1 (en) 2002-01-17
AU2001264612B2 (en) 2007-02-22
NO20030128L (en) 2003-03-12
AU2001264612B8 (en) 2007-02-22
NO20030128D0 (en) 2003-01-10
JP2004502742A (en) 2004-01-29
KR20030031957A (en) 2003-04-23
IL153764A0 (en) 2003-07-06
AU2001264612C1 (en) 2007-11-22
WO2002004021A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
SG136804A1 (en) Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
MX9700534A (en) Use of droloxifene for the treatment of prostatic diseases, endometriosis and obesity.
MY137757A (en) Therapeutic treatment
CO4290346A1 (en) Azithromycin Controlled Release Dosage Forms
SG170612A1 (en) Antineoplastic combinations
DK0703786T3 (en) Use of nona- and decapeptides for the manufacture of a medicament for the treatment of AIDS
MXPA04003674A (en) Improved use of antitumoral compound in cancer therapy.
IL155781A0 (en) Effective antitumor treatments
DK1930022T3 (en) Treatment of bladder fibrosis with antibodies against alpha-V-beta-6 integrin
MY164077A (en) Compositions and uses of et743 for treating cancer
DE69815310D1 (en) PREPARATIONS FOR TUMOR TREATMENT CONTAINING SHARK CARTILAGE EXTRACTS AND ANTINEOPLASTIC AGENTS
MY138883A (en) Use of asiatic acid for treatment of cencer
MXPA03011306A (en) METHODS FOR PREPARATION AND USE OF 1alpha,24(S)-DIHYDROXYVITAMIN D2.
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
TR200103432T2 (en) Blocking monoclonal VLA-1 antibody and its use in the treatment of inflammatory diseases.
GB9521608D0 (en) Pharmaceutical composition
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
YU29803A (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
IL139144A0 (en) Mycobacterial inhibitors
AU5434899A (en) Cancer treatment
CY1109852T1 (en) CALCIUM SUPPLEMENT FOR LIMITATION OF PROTECTOR CANCER RISK
ES1034645U (en) Anti-radiation glycodental protector
AU2003229876A1 (en) Tumour associated antigens